Drug Interactions With Tamoxifen and Treatment Effectiveness in Premenopausal Breast Cancer Patients: A Bayesian Joint Modeling Approach
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70157 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Kirsten M Woolpert und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Tamoxifen, Breast Neoplasms, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Danmarks Frie Forskningsfond, US National Institute for General Medical Sciences.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Tamoxifen is guideline treatment for premenopausal women with estrogen receptor‐positive (ER+) breast cancer. Therapeutic efficacy relies partly on tamoxifen biotransformation by CYP2D6, CYP2C19, and CYP3A4 enzymes. We conducted a cohort study to evaluate whether concomitant prescription of drugs that inhibit these enzymes impacted breast cancer recurrence.
Methods
We enrolled 4493 premenopausal women with stage I–III ER+ breast cancer (2002–2011) treated with tamoxifen. We defined time‐varying CYP‐inhibiting drug exposures as the proportion of overlapping days during the tamoxifen treatment period. We estimated associations of concomitant medication use with recurrence using: (1) Bayesian joint modeling (hazard ratio [HR] and 95% credible intervals [95% CrI]), (2) traditional Cox regression (HR and 95% confidence intervals [95% CI]).
Results
During tamoxifen therapy, 13% of the cohort used strong CYP2D6 inhibitors, 31% weak CYP2D6 inhibitors, 37% CYP2C19 inhibitors, and 12% CYP3A4/5 inhibitors. Bayesian joint models showed that women with ≥ 50% overlap between tamoxifen and CYP2D6 inhibitors had increased recurrence risk compared with 0% overlap (HR: 1.24, 95% CrI: 0.96, 1.58). No recurrence association was seen for CYP2C19 inhibitors (≥ 50% vs. 0%, HR = 1.0, 95% CrI: 0.69, 1.40), but traditional Cox models yielded positive associations for CYP2C19 overlap (≥ 50% vs. 0%, HR = 1.45, 95% CI: 1.07, 1.96). With Bayesian joint models, we observed no association between ≥ 50% versus 0% overlap with CYP3A4/5 inhibitors (HR: 0.84, 95% CrI: 0.32, 1.93).
Conclusions
With Bayesian joint modeling, we saw a slight increase in recurrence among CYP2D6‐inhibitor users, but no increase among CYP2C19‐ or CYP3A4‐inhibitor users. Results from Cox regression models were less plausible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.
- Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
- Department of Pathology, Aarhus University Hospital, Aarhus, Denmark.
- Danish Breast Cancer Group, Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
ORCID-Profile: Per Damkier
Förderung
- NCI NIH HHS
- Danmarks Frie Forskningsfond
- US National Institute for General Medical Sciences
- Mary Kay Ash Foundation
- Lundbeck Foundation
- Susan G. Komen for the Cure
- National Cancer Institute
Zitieren
APA
Woolpert, K. M., Cronin-Fenton, D. P., Damkier, P., Kjærsgaard, A., Hamilton-Dutoit, S., Ejlertsen, B., MacLehose, R. F., Christiansen, P., Silliman, R. A., Lash, T. L., Ahern, T. P., & Collin, L. J. (2025). Drug Interactions With Tamoxifen and Treatment Effectiveness in Premenopausal Breast Cancer Patients: A Bayesian Joint Modeling Approach. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70157
Vancouver
Woolpert KM, Cronin-Fenton DP, Damkier P, Kjærsgaard A, Hamilton-Dutoit S, Ejlertsen B, et al. Drug Interactions With Tamoxifen and Treatment Effectiveness in Premenopausal Breast Cancer Patients: A Bayesian Joint Modeling Approach. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70157
BibTeX
@article{Woolpert2025,
author = {Woolpert, Kirsten M and Cronin-Fenton, Deirdre P and Damkier, Per and Kjærsgaard, Anders and Hamilton-Dutoit, Stephen and Ejlertsen, Bent and MacLehose, Richard F and Christiansen, Peer and Silliman, Rebecca A and Lash, Timothy L and Ahern, Thomas P and Collin, Lindsay J},
title = {Drug Interactions With Tamoxifen and Treatment Effectiveness in Premenopausal Breast Cancer Patients: A Bayesian Joint Modeling Approach},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70157}
}
EUVIMED